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DOI 10.1016/j.ccr.2010.08.012SUMMARYCyclin D1 elicits transcriptional effects through inactivation of the retinoblastoma protein and direct associ-
ation with transcriptional regulators. The current work reveals a molecular relationship between cyclin
D1/CDK4 kinase and protein arginine methyltransferase 5 (PRMT5), an enzyme associated with histone
methylation and transcriptional repression. Primary tumors of a mouse lymphoma model exhibit increased
PRMT5 methyltransferase activity and histone arginine methylation. Analyses demonstrate that MEP50,
a PRMT5 coregulatory factor, is a CDK4 substrate, and phosphorylation increases PRMT5/MEP50 activity.
Increased PRMT5 activity mediates key events associated with cyclin D1-dependent neoplastic growth,
including CUL4 repression, CDT1 overexpression, and DNA rereplication. Importantly, human cancers
harboring mutations in Fbx4, the cyclin D1 E3 ligase, exhibit nuclear cyclin D1 accumulation and increased
PRMT5 activity.INTRODUCTION
Cyclin D1, the allosteric regulator of CDK4 and CDK6, is an inte-
gral mediator of growth factor-dependent G1-phase progres-
sion. Growth factor stimulation induces cyclin D1 expression,
association with CDK4, and nuclear accumulation during mid-
G1; active cyclin D1/CDK4 kinase catalyzes phosphorylation-
dependent inactivation of the retinoblastoma (RB) family pro-
teins (Diehl, 2002). Following the G1/S transition, cyclin D1
accumulation is opposed by Pro287-directed phosphorylation
of threonine-286 (T286) by glycogen synthase kinase 3b
(GSK3b), which promotes its nuclear export (Alt et al., 2000).Significance
Cyclin D1 contributes to cell growth through phosphorylation o
scriptional regulators. Our work demonstrates that direct reg
transformation depends on cyclin D1 activation of CDK4. The
netic regulation of target genes associated with cancer esta
expression occurs independently of RB yet remains kinase d
repression in concert with the repressive nature of PRMT5-
PRMT5/MEP50 is one key effector of cyclin D1-dependent ge
CCytoplasmic, phosphorylated cyclin D1 is polyubiquitylated by
SCFFbx4 and degraded by the 26S proteasome (Lin et al., 2006).
Overexpression of cyclin D1 occurs in numerous human
malignancies, including carcinomas of the breast, esophagus,
colon, and lung (Bani-Hani et al., 2000; Bartkova et al., 1994a;
Bartkova et al., 1995; Bartkova et al., 1994b; Gillett et al.,
1994; Herman et al., 1995; Hibberts et al., 1999; Hosokawa
and Arnold, 1998; Hosokawa et al., 1999; Jin et al., 2001).
Although overexpression of cyclin D1 is often observed, overex-
pression per se is insufficient to drive spontaneous transforma-
tion. The primary cellular mechanism that restricts cyclin D1/
CDK4 activity is cytoplasmic, ubiquitin-mediated degradationf the retinoblastoma protein and direct association with tran-
ulation of critical target genes associated with neoplastic
identification of a CDK4 substrate that contributes to epige-
blishes a paradigm whereby cyclin D1 regulation of gene
ependent. The association of cyclin D1 with transcriptional
dependent histone methylation supports a model wherein
ne expression during neoplastic growth.
ancer Cell 18, 329–340, October 19, 2010 ª2010 Elsevier Inc. 329
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Regulation of PRMT5 by Cyclin D1/CDK4of cyclin D1 during S-phase. Mutations that disrupt this event
directly contribute to neoplastic growth (Aggarwal et al., 2007;
Alt et al., 2000; Barbash et al., 2008; Benzeno et al., 2006; Lu
et al., 2003). Specifically, inhibition of cyclin D1 proteolysis during
S-phase via mutations within the cyclin D1 degron or inactivation
of the cyclin D1 E3 ligase, Fbx4, triggers constitutive nuclear
accumulation of active cyclin D1/CDK4 complexes, which, in
turn, disrupt temporal regulation of DNA replication, thereby
contributing to neoplastic growth. The disruption of S-phase
fidelity reflects accumulation of the replication-licensing protein
CDT1. Inappropriate CDT1 stabilization is a result of nuclear
cyclin D1/CDK4-dependent repression of CUL4A and CUL4B,
encoding scaffolding proteins for the E3 ligase that directs
CDT1 degradation during S-phase (Aggarwal et al., 2007).
Numerous previous studies have linked cyclin D1 with tran-
scriptional repression. The current model focuses on an intrinsic
capacity of cyclin D1 to associate directly with transcriptional
regulators and either interfere with the recruitment of cofactors
that direct gene repression or, conversely, facilitate coactivator
recruitment as observed in the collaboration between cAMP
signaling and cyclin D1 in the activation of estrogen receptor
(ER)-mediated transcription in mammary epithelial cells (Lamb
et al., 2000). The strongest evidence for cyclinD1directly contrib-
uting to the regulation of gene expression stems from recentwork
utilizing genome-wide chromatin immuneprecipitation to identify
promoters occupied by cyclin D1 (Bienvenu et al., 2010).
A common theme throughout previous studies is that cyclin D1
modulates gene expression in a kinase-independent manner.
However, transcriptional repression of CUL4A and CUL4B by
cyclin D1 requires S-phase accumulation of catalytically active
cyclin D1/CDK4 (Aggarwal et al., 2007). The current study
dissects the molecular mechanism of CUL4A/B transcriptional
regulation by cyclin D1 and its contribution to nuclear cyclin
D1-driven neoplastic growth.RESULTS
Association of the PRMT5/MEP50 Methyltransferase
with Cyclin D1T286A/CDK4
To decipher mechanisms of nuclear cyclin D1-driven neoplasia,
we immunopurified cyclin D1T286A complexes from tumors
derived from Em-D1T286A transgenic mice (Gladden et al.,
2006) and identified copurifying proteins by mass spectrometry
(see Figure S1A available online). Given previous reports linking
cyclin D1 with transcriptional repression, we were intrigued by
copurification of PRMT5, a Type II methyltransferase, along
with MEP50, a WD40 repeat-containing protein that contributes
to PRMT5 activity and substrate recruitment (peptides recov-
ered are shown in Table S1; Krause et al., 2007). Coprecipitation
of cyclin D1T286A, CDK4, MEP50, and PRMT5 from B cell
tumors confirmed the interaction (Figures 1A and 1B). To ascer-
tain the existence of this complex in human cancer cells, we
used TE3 and TE7 cell lines that harbor cyclin D1P287A (Ben-
zeno et al., 2006). Cyclin D1P287A is refractory to GSK3b-
dependent phosphorylation and is stabilized in the nucleus,
analogous to D1T286A. Consistent with the above results, we
also observed coprecipitation of cyclin D1P287A along with
MEP50, PRMT5, and CDK4 (Figure 1C).330 Cancer Cell 18, 329–340, October 19, 2010 ª2010 Elsevier Inc.Association of cyclin D1T286A with PRMT5, in concert with
previous work demonstrating that cyclin D1T286A reduces
CUL4A/B expression in a CDK4-dependent manner (Aggarwal
et al., 2007), suggested a potential regulatory relationship
involving cyclin D1T286A and chromatin-modifying proteins.
To interrogate this putative relationship, we coexpressed Myc-
PRMT5 together with CDK4 and either wild-type cyclin D1 or
D1T286A in HeLa cells. Following synchronization at the G1/S
boundary and release into S-phase, complexes were immune
precipitated, and associated proteins were identified by immu-
noblot. Cyclin D1T286A was enriched in PRMT5 complexes at
the G1/S boundary and declined as cells progressed through
S-phase (Figure 1D; Figure S1B). In contrast, low levels of
wild-type cyclin D1 were associated with PRMT5, with no
obvious enrichment. The reduced binding of wild-type cyclin
D1 reflects both its low abundance, due to proteolysis during
S-phase, and cytoplasmic localization of the remaining protein
(Alt et al., 2000; Barbash et al., 2008).
To determine whether known components of chromatin-
remodeling complexes were also present in the cyclin D1T286A-
PRMT5 complex, we performed a two-step affinity purification of
this complex. Initially, Flag-D1T286A-containing complexes
were collected frompooled tumor lysates byM2-affinity chroma-
tography, which was used to isolate flag-tagged cyclin D1.
Complexes were eluted with flag peptide then reprecipitated
with PRMT5 antibodies. In addition to the expected components
(cyclin D1T286A, CDK4, PRMT5, and MEP50) we also noted
Brg1 (Figure 1E). Importantly, these complexes do not contain
RB, PRMT5-related PRMT1 and PRMT7, mSin3a (a component
of large multisubunit histone deacetylase [HDAC] corepressor
complexes), or Mi2 (a nucleosome remodeling and HDAC com-
plex component) (Figure 1E). This result reveals the existence of
a cyclin D1T286A, CDK4, MEP50, PRMT5, and Brg1 complex.
Consistently, we also noted coprecipitation of Brg1 with endog-
enous cyclin D1P287A in TE3 and TE7 cells (Figure 1C). Consis-
tently, size exclusion chromatography revealed cofractionation
of cyclin D1T286A, CDK4, PRMT5, MEP50, and Brg1 in murine
lymphomas (Figure S1C).PRMT5/MEP50 Mediates Cyclin D1T286A/
CDK4-DependentCUL4A/B Loss and CDT1 Stabilization
Because PRMT5-dependent dimethylation of histone H3 argi-
nine 8 (H3R8) and histone H4 arginine 3 (H4R3) is associated
with transcriptional repression (Pal et al., 2004), we considered
whether PRMT5 would mediate cyclin D1T286A/CDK4-depen-
dent repression of CUL4A/B. We first used the general methyl-
transferase inhibitor 50 Deoxy-500-methyl-thioadenosine (MTA;
Hou et al., 2008; Iwasaki and Yada, 2007) following identification
of a concentration that inhibited H4R3 methylation but not H3K4
methylation (Figure 2A). As previously observed, expression of
catalytically active cyclin D1T286A/CDK4 resulted in the mainte-
nance of CDT1 and loss of CUL4A/B proteins and mRNAs
specifically during S-phase (Figures 2B–2D). Treatment with
100 mM MTA restored CUL4A/B proteins and mRNAs (Figures
2B–2D) and triggered CDT1 degradation during S-phase
(Figure 2B). A similar restoration of CUL4A/B was observed
with another PRMT inhibitor, AMI-1 (Cheng et al., 2004) (Figures
S2A–S2D).
Figure 1. Identification of Cyclin D1T286A/
PRMT5/MEP50 Complexes
(A) M2 (anti-Flag) purified complexes from Em-
D1T286A (Flag epitope) transgenic tumors and
nontransgenic spleens were blotted for PRMT5
and cyclin D1.
(B) MEP50 immunoprecipitates (IP, 1 mg whole-
cell lysate input) prepared from Em-D1T286A
transgenic tumors were immunoblotted as indi-
cated.
(C) MEP50 IP (1.5mg whole cell lysate input) from
human esophageal cancer cell lines TE3 and TE7
were immunoblotted as indicated (top panel).
Input lysates have been shown in the bottom
panel.
(D) HeLa cells transfected with either wild-type cy-
clin D1 or D1T286A along with myc-PRMT5 and
CDK4 were synchronized with aphidicolin. Cells
were collected at 0 hr (G1/S boundary) and 4 hr
(S-phase) after release. Myc-PRMT5 was pulled
down with myc antibody (1 mg whole cell lysate
input) and immunoblotted as indicated (right
panel); input lysates are shown in left panel.
(E) Cyclin D1/CDK4 complexes were isolated from
Em-D1T286A lymphomas using M2-agarose fol-
lowed by elution with Flag peptide. Eluted
complexes were immunoprecipitated with normal
rabbit serum (NRS) or PRMT5 antibody; 300 mg of
eluted complex served as input in NRS or PRMT5
IP, and western blot analysis was performed as
indicated. See also Figure S1 and Table S1.
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Regulation of PRMT5 by Cyclin D1/CDK4As an independent assessment of PRMT5 function, we
utilized siRNA directed at PRMT5 or MEP50. Knockdown of
PRMT5 (Figures 2E, 2G, and 2H) or MEP50 (Figure S2E)
restored expression of CUL4A/B and CDT1 loss during S-
phase. Knockdown of PRMT5 also reduced H4R3 and H3R8
methylation but did not change levels of PRMT1, 2, and 7
(Figure 2E). We confirmed previous observations that regulation
of CUL4 and CDT1 requires the kinase activity of CDK4 given
that expression of a kinase defective mutant, CDK4(K35M),
does not support cyclin D1T286A-dependent CUL4 loss and
eliminates the impact of PRMT5 knockdown (Figure 2F). Further
supporting a role for PRMT5 activity downstream of cyclin D1,
esophageal cancer cells harboring the mutant cyclin D1 P287A
exhibited increased CDT1, decreased CUL4A, and increased
H4R3 methylation compared to cells with wild-type cyclin D1
(Figure S2F).
Because attenuation of PRMT5 relieves CUL4 repression, we
questioned whether cyclin D1T286A regulates HDAC activity,
contributing to CUL4 repression. Synchronized HeLa cellsCancer Cell 18, 329–340,were treated with the HDAC inhibitors
sodium butyrate, trichostatin A, and
nicotinamide; each inhibitor increased
CUL4 expression independently of cyclin
D1T286A (Figures S2G and S2H). Fur-
thermore, acetylation of histone H3 and
H4 within the CUL4A promoter (Fig-
ure S2I) and CUL4B promoter (data not
shown) was not influenced by cyclin
D1T286A, suggesting that HDAC activityis not coordinately regulated with histone arginine methylation
by cyclin D1T286A/CDK4 at the CUL4 promoters.
CyclinD1T286A/CDK4KinaseDirects IncreasedPRMT5
Activity and PRMT5-Dependent Methylation
of CUL4 Promoters
If PRMT5 mediates the action of cyclin D1T286A/CDK4 in vivo,
we reasoned that increased H3R8 dimethylation, a PRMT5-
specific mark (Pal et al., 2004), should be apparent in tumors
derived from Em-D1T286A mice. Methylated H3R8 was elevated
in tumors compared to nontransgenic controls (Figure 3A and
Figure S3A; see Figure S3C for H3R8 antibody specificity). To
determine whether increased methylation of histones reflected
increased PRMT5 activity, we assessedmethyltransferase activ-
ity of PRMT5 immunopurified from control or tumor-burden
spleens and found that four of six tumors exhibited an increase
in PRMT5 activity (Figure 3B). Although PRMT5 levels are
increased in cyclin D1T286A tumors, it does not appear sufficient
to account for the dramatic increase in PRMT5 catalysisOctober 19, 2010 ª2010 Elsevier Inc. 331
Figure 2. PRMT5/MEP50 Mediates Cyclin
D1T286A/CDK4-Dependent CUL4 Repres-
sion and CDT1 Stabilization
(A) HeLa cells were treated withMTA (50 Deoxy-500-
methyl-thioadenosine) with concentrations
ranging from 100 to 300 mM for 48 hr or vehicle
DMSO. The cells were analyzed by western blot-
ting as indicated.
(B) HeLa cells cultured for 24 hr in the absence or
presence of 100 mM MTA were transfected with
vectors encoding cyclin D1 or D1T286A and
CDK4. Twenty-four hours after transfection, cells
were synchronized with nocodazole for 16–18 hr;
mitotic cells were then separated in two dishes.
One was harvested 8 hr after release (G1-phase).
Hydroxyurea was added to the second after
release and harvested at 14 hr to obtain cells in
S-phase; lysates were subjected to immunoblot
as indicated.
(C and D) RNA was collected from HeLa cells
treated as in (B). The bars illustrate CUL4A (C)
and CUL4B (D) mRNA levels with MTA treatment
(first bar) and without MTA treatment (second
bar) as analyzed by real-time PCR. One represen-
tative experiment of three biological independent
experiments is presented.
(E) HeLa cells were treated with or without
siPRMT5 then transfected with wild-type cyclin
D1 or D1T286A plasmids along with CDK4. Cells
were synchronized as in (B) and were immunoblot-
ted as indicated.
(F) HeLa cells were treated with siPRMT5 or si
control for 24 hr, followed by transfection with cy-
clin D1T286A along with CDK4 or kinase dead
CDK4(K35M) plasmids. Cells were synchronized
as in (B), and lysates were immunoblotted as indi-
cated.
(G and H) Same as (C) and (D), except that cells
were analyzed with and without siPRMT5 treat-
ment. See also Figure S2.
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Regulation of PRMT5 by Cyclin D1/CDK4observed. We also observed increased methylation of recombi-
nant H3R8 in vitro (Figure S3B). To more directly determine
whether this increase reflects the action of cyclin D1T286A/
CDK4, we reconstituted this pathway in HeLa cells. Consistently,
PRMT5 isolated from S-phase cells expressing cyclin D1T286A
exhibited enhanced methyltransferase activity; a small but
significant increase was also observed in cells overexpressing
wild-type cyclin D1/CDK4 (Figure 3C).
Given the increase in total H4R3/H3R8 methylation, we deter-
mined whether there was an increase in H4R3/H3R8methylation
on the proximal CUL4A/B promoter regions by ChIP using anti-332 Cancer Cell 18, 329–340, October 19, 2010 ª2010 Elsevier Inc.bodies detecting dimethylated H4R3
and dimethylated H3R8 (see Figure S3D
for primer design). We observed an 2-
to 3-fold increase in methylation of both
H4R3 and H3R8 at the proximal promoter
regions (500 bp upstream of the first
coding exon) of CUL4A (Figure 3D) and
CUL4B (Figure S3E) in the presence of
cyclin D1T286A/CDK4 as compared to
cyclin D1/CDK4 or untransfected con-trols in S-phase HeLa cells. No enrichment was detected with
primers directed to regions corresponding to 1000 bp upstream
(data not shown) or 5000 bp upstream of first coding exon of
CUL4A/B (control/blue bars Figures 3D; Figure S3E). Using
PRMT5-specific antibodies for ChIP, we noted PRMT5 occu-
pancy of the same region of the CUL4 promoters (Figure S3F).
Critically, siRNA-mediated knockdown of PRMT5 resulted in
significant attenuation of cyclin D1T286A/CDK4-dependent
H4R3/H3R8 methylation at CUL4A/B promoter regions during
S-phase (Figure 3E). In agreement with cyclin D1T286A directly
contributing to increased PRMT5 activity, cyclin D1T286A
Figure 3. Cyclin D1T286A/CDK4 Activity Increases PRMT5 Methyltransferase Activity In Vivo
(A) Nontransgenic spleen or cyclin D1T286A-driven splenic lymphoma lysates were immunoblotted as indicated.
(B) Methyltransferase activity of tumor-derived PRMT5 using recombinant histone H4 as the substrate.
(C) Same as (B), except that PRMT5 complexes were immunopurified from HeLa cells transfected with the indicated plasmids and synchronized in S-phase.
(D–F) ChIP primer sets (1, 2, and 3) were designed to span 1000–2000 bp upstream of the first coding exon of eitherCUL4A orCUL4B, respectively (primer design,
Figure S3D). Primer set 3 was used for both CUL4A and CUL4B ChIP assays. Control primer sets were designed 5000 bp upstream of first coding exon of
CUL4A/B. The CUL4A/B promoter primer (red bar) and control primer (blue bar) are displayed in all graphs. ChIP was performed for CUL4A (Figure 3D) and
CUL4B (Figure S3E) with antibodies directed to dimethyl H4R3 (Figure 3D, top panel), H3R8 (Figure 3D, bottom panel; Figure S3E, right panel), or normal mouse
IgG (first 6 bars of each graph), on chromatin prepared from synchronized HeLa cells expressing wild-type cyclin D1/CDK4, D1T286A/CDK4, or untransfected
cells. DNA-protein immunoprecipitates and 5% of input chromatin were analyzed by qPCR for both CUL4A and CUL4B promoter regions. PCR values represent
percentage of input. One representative experiment of three biological independent experiments is presented.
(E) PRMT5 knockdown attenuates methylation of H4R3 and H3R8 ofCUL4A (top graph) andCUL4B (bottom graph) promoter regions. ChIP was performed using
dimethyl specific H4R3 and H3R8 antibodies as described in (D); two representative experiments are shown.
(F)DetectionofcyclinD1T286Aon theCul4A/BproximalpromoterbyFlagChIP fromEm-D1T286Atumors.Two independentexperimentsareshown.SeealsoFigureS3.
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Regulation of PRMT5 by Cyclin D1/CDK4
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Figure 4. Cyclin D1/CDK4 Kinase Phos-
phorylates MEP50 In Vitro and In Vivo
(A) MEP50 was precipitated from HeLa cells trans-
fected with vectors encoding cyclin D1, D1T286A
along with either CDK4 or kinase dead CDK4
(K35M) and synchronized in S-phase by sequen-
tial nocodazole and HU treatment. MEP50 phos-
phorylation was assessed using a commercially
available phospho-SP/TP antibody. The arrow
indicates the mobility of phospho-MEP50, which
migrates faster than the asterisk-indicated
nonspecific immunoreactive band. Total MEP50,
PRMT5, and cyclin D1 present in immune
complexes were assessed with appropriate anti-
bodies.
(B) Phosphorylation of recombinant MEP50 or RB
by cyclin D1/CDK4 or D1T286A/CDK4. Substrate
phosphorylation was assessed by SDS-PAGE fol-
lowed by autoradiography.
(C) Cyclin D1T286A/CDK4 phosphorylation of
MEP50 at Thr-5, Ser-264, and Ser-306 in vitro.
(D) Acute expression of MEP50 mutants Thr-5A
and Ser-264A inhibit cyclin D1T286A/CDK4-
dependent repression of CUL4 and CDT1 stabili-
zation. See also Figure S4.
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Regulation of PRMT5 by Cyclin D1/CDK4occupancy of both Cul4A/B promoters was observed in cyclin
D1T286A-expressing primary murine lymphoma cells (Fig-
ure 3F). Consistent with the presence of Brg1 in the cyclin
D1T286A/PRMT5 complex, Brg1 also occupies the Cul4A and
Cul4B promoters (Figure S3G).
Phosphorylation of MEP50 by Cyclin D1T286A/CDK4
In Vitro and In Vivo
We next considered whether either MEP50 or PRMT5 might
be a cyclin D1/CDK4 substrate. PRMT5/MEP50 complexes
were precipitated from HeLa cells expressing cyclin D1 or cyclin
D1T286A along with either CDK4 or CDK4(K35M) with a MEP50
antibody. Upon immunoblotting with an antibody detecting
phosphorylated serine or threonine when either residue is fol-
lowed by a proline, we noted a band in cells expressing cyclin
D1T286A/CDK4 that migrated with the expected mobility of
MEP50 (Figure 4A, noted by arrow). No such band was apparent
in cyclin D1-expressing cells or in cyclin D1T286A/CDK4(K35M)-
expressing cells. In addition, we did not detect any apparent
p-SP/TP signal corresponding to PRMT5.
MEP50 contains four putative CDK phosphorylation sites:
Thr-5, Ser-176, Ser-264, and Ser-306 (Figure S4A). Consistent
with MEP50 being a direct substrate, recombinant MEP50 was
phosphorylated by cyclin D1/CDK4 and D1T286A/CDK4 in vitro
(Figure 4B; Figure S4B). To identify phosphorylated residues, we
phosphorylated recombinant MEP50 in vitro with purified cyclin
D1T286A/CDK4 and subjected it to mass spectometry; we also
affinity purified MEP50 from cells coexpressing cyclin D1T286A/
CDK4 for the same analysis. Both approaches revealed phos-
phorylation ofMEP50 at Thr-5 (Figures S4C–S4D).We generated
recombinant MEP50 proteins harboring alanine substitutions at
all four putative CDK phosphorylation sites and used these as
substrates. Mutation of Thr-5 dramatically reduced phosphate
incorporation; mutation of Ser-264 and Ser-306 also resulted in334 Cancer Cell 18, 329–340, October 19, 2010 ª2010 Elsevier Inc.amoderate reduction, whereas Ser-176A had no apparent effect
(Figure 4C).
If CUL4 repression and CDT1 stabilization depends on
MEP50 phosphorylation by cyclin D1T286A/CDK4, we reasoned
that overexpression of key nonphosphorylatable MEP50
mutants should be inhibitory. Indeed, expression of myc-tagged
MEP50-T5A and, to a lesser degree, MEP50-S264A interfered
with cyclin D1T286A-dependent CDT1 stabilization and CUL4
loss during S-phase (Figure 4D). Collectively, these results reveal
that MEP50 is a CDK4 substrate and that phosphorylation of
MEP50 predominantly on Thr-5 dominantly mediates down-
stream function.
Cyclin D1T286A/CDK4 Regulates PRMT5
Methyltransferase Activity via MEP50 Phosphorylation
To determine whether phosphorylation of MEP50 can directly
regulate PRMT5 methyltransferase activity independently of
association with high-molecular-weight chromatin remodeling
complexes, we performed coupled in vitro kinase/methyltrans-
ferase reactions with purified recombinant PRMT5/MEP50 pro-
duced in Sf9 cells. PRMT5-dependent methyltransferase activity
was increased following a kinase reaction with purified cyclin
D1T286A/CDK4 (Figure 5A). Additionally, increased PRMT5/
MEP50 SAM-dependent methyltransferase activity directed
toward histone H4 was readily apparent following incubation of
PRMT5/MEP50 complexes purified from HeLa cells with cyclin
D1T286A/CDK4 and, to a lesser degree, with cyclin D1/CDK4
(Figure 5B). To evaluate the role of MEP50 phosphorylation, we
expressed either wild-type MEP50 or mutant MEP50 alleles in
cells treated with MEP50 siRNA. Expression of MEP50-T5A
maintained basal methyltransferase activity in vitro but was
refractory to the CDK4-dependent increase of PRMT5 activation
(Figure 5C). Serine-264 to alanine substitution also attenuated
the response to cyclin D1T286A/CDK4, whereas alanine
Figure 5. Cyclin D1T286A/CDK4 Increases
PRMT5 Methyltransferase Activity through
MEP50
(A and B) Purified cyclin D1/CDK4 and D1T286A/
CDK4 kinases increase catalytic activity of
PRMT5/MEP50 in vitro. Purified cyclin/CDK4
complexes from Sf9 cells were mixed with purified
recombinant PRMT5/MEP50 produced in Sf9 cells
(A) or PRMT5 complexes purified from HeLa cells
(B) and incubated for 30 min with ATP at 30C.
PRMT5 complexes were washed and methyl-
transferase activity assessed using 3H-Me (SAM)
and recombinant Histone H4.
(C) Same as (B), except PRMT5 was purified
from HeLa cells following MEP50 knockdown and
re-expression of the indicated MEP50 mutants.
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Regulation of PRMT5 by Cyclin D1/CDK4substitution at 176/306 was without influence. These results
demonstrate that cyclin D1/CDK4 can increase histone methyl-
transferase activity of PRMT5/MEP50 through phosphorylation
of Thr-5 and perhaps through Ser-264.PRMT5/MEP50 Mediates Cyclin D1T286A-Dependent
Rereplication, Transformation, and Survival of Cyclin
D1T286A-Expressing Lymphoma Cells
Cyclin D1T286A/CDK4 expression induces rereplication in
a CDT1-dependent fashion (Aggarwal et al., 2007). If PRMT5/
MEP50 mediates rereplication, knockdown of PRMT5 should
be inhibitory. Consistent with this hypothesis, we observed a
dramatic reduction of >4N population from 26.8% to 2.28%
with PRMT5 knockdown in T286A/CDK4/CDT1-transfected
HeLa cells (Figures 6A and 6B).
We next determined whether PRMT5 mediates cyclin
D1T286A-dependent transformation by knockdown of PRMT5
in murine fibroblasts, concurrent with expression of oncogenic
RasV12 and cyclin D1T286A. Indeed, although cotransfection
of both RasV12 and cyclin D1T286A induced focus formation
(Figure 6C), foci number was reduced by 50% following knock-
down of PRMT5. PRMT5 knockdown was not accompanied by
cell cycle arrest (Figure S5A), suggesting that foci reduction is
not a consequence of cell cycle arrest. In addition, PRMT5
knockdown did not significantly attenuate transformation medi-
ated by Ras plus c-Myc, suggesting mechanistic specificity
between PRMT5-dependent methyltransferase activity and
constitutively nuclear cyclin D1 (Figure 6C).Cancer Cell 18, 329–340,To investigate therapeutic potential
of targeting PRMT5, we determined
whether inhibition of PRMT5 would com-
promise survival of primary Em-D1T286A
lymphoma cells ex vivo. Because we
were unable to efficiently introduce
siRNA into these primary tumor cells,
we utilized AMI-1. AMI-1 treatment
increased death of tumor cells relative
to normal controls (Figure 6D). In addi-
tion, treatment of primary lymphoma cells
with MTA also triggered increased cell
death relative to untreated tumor cells
or MTA treated control lymphocytes(Figure S5B). Together, these observations suggest that
PRMT5 plays an important role in promoting cyclin D1T286A/
CDK4-dependent DNA rereplication, cell transformation, and
survival of cells harboring constitutively active cyclin D1/CDK4.
To examine the role of MEP50 phosphorylation in cyclin
D1T286A-dependent transformation, wild-type or phosphoryla-
tion-deficient T5A or S264A mutant MEP50 was coexpressed
with RasV12 and cyclin D1T286A in NIH 3T3 cells. Compared
to wild-type MEP50, expression of the T5A or S264A MEP50
mutant significantly reduced foci number, suggesting that phos-
phorylation of MEP50 and subsequent increase in PRMT5
activity is a driving force for cellular transformation in the pres-
ence of cyclin D1T286A (Figure 6E).
Fbx4 Inactivation Promotes Increased
PRMT5-Dependent Histone Methylation
Although mutations directly targeting cyclin D1 do occur in
human cancer (Benzeno et al., 2006), they occur infrequently
relative to inactivation of the cyclin D1 E3 ligase (Barbash
et al., 2008). Because inactivation of Fbx4 also drives nuclear
accumulation of cyclin D1 kinase during S-phase, we postulated
that Fbx4 loss should also impact PRMT5 function. We initially
assessed this hypothesis in NIH 3T3 cells harboring Fbx4 shRNA
(Lin et al., 2006). Fbx4 knockdown increased cyclin D1 andCDT1
and decreased CUL4A/B; critically, the level of H4R3 methyla-
tion was dramatically increased (Figure 7A). Previous work iden-
tified esophageal tumors harboring inactivating mutations in
Fbx4 that resulted in strong cyclin D1 overexpression (BarbashOctober 19, 2010 ª2010 Elsevier Inc. 335
Figure 6. PRMT5 Knockdown Inhibits
Cyclin D1T286A-Dependent DNA Rereplica-
tion, Cell Transformation, and Increases
Death of Tumor Cells
(A) Following transfection of HeLa cells with the
indicated expression plasmids, TA (D1T286A),
K4 (CDK4), K35M (CDK4(K35M)), CDT1, cell cycle
profile was assessed by FACS after PI staining.
(B) Graphical representation of the flow cytometry
data from (A). The bars show the percentage of
cells showing >4N DNA content.
(C) Foci formation assay was performed by
concurrent knockdown of murine PRMT5 and
overexpression of the indicated proteins in NIH
3T3 cells. Cells were grown for 14 days and
stained with Giemsa to visualize foci. Quantifica-
tion of data has been shown. Error bars represent
standard deviation, and asterisk indicates p <
0.05.
(D) Single-cell suspensions of splenocytes
prepared from nontransgenic or malignant Em-
D1T286A transgenic tumor-burdened spleens
were treated with 200 mM arginine methyltransfer-
ase inhibitor AMI-1. The cells were analyzed for the
inhibitor sensitivity by measuring the percentage
of cell death via AnnexinV –PI staining/flow cytom-
etry. Values represent the mean of three indepen-
dent experiments with error bars indicating ± SD .
(E) Foci formation assay was performed by trans-
fection of the indicated MEP50 constructs along
with empty vector control or RasV12 plus cyclin
D1T286A in NIH 3T3 cells. Cells were grown for
14 days, and foci were analyzed as in (C). See
also Figure S5.
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Regulation of PRMT5 by Cyclin D1/CDK4et al., 2008). We chose these same tumors to ascertain whether
loss of Fbx4 function and overexpression of wild-type cyclin D1
kinase also correlated with increased H4R3 methylation. Immu-
nohistochemical staining on tumor sections revealed a marked
increase in H4R3 methylation relative to an esophageal tumor
harboring wild-type Fbx4 or normal esophageal epithelium
(Figure 7B). Because our analysis was restricted to tumors with
known Fbx4 mutations and tissue availability for IHC (n = 4),
our analysis did not achieve statistical significance. To sup-
port this analysis, we analyzed an esophageal tumor cell line
harboring a mutant Fbx4, Fbx4(S8R) (TE10; Barbash et al.,
2008) and another expressing both wild-type Fbx4 and cyclin
D1 (TE15) and found that inactive Fbx4 correlates with increased
CDT1 and methylated H4R3 (Figure 7C). Together, these obser-
vations demonstrate that stabilized nuclear cyclin D1 resulting
from either cyclin D1 mutation or inactivation of Fbx4 results in
increased PRMT5-dependent histone methylation.336 Cancer Cell 18, 329–340, October 19, 2010 ª2010 Elsevier Inc.DISCUSSION
Cyclin D1 is subject to intricate posttrans-
lational control to ensure its temporal
regulation. Cyclin D1 nuclear export fol-
lowed by Fbx4-dependent ubiquitylation
and degradation during S-phase are key
features that serve to restrain nuclear
cyclin D1/CDK4 activity and ensure nor-mal cell division (Alt et al., 2000; Benzeno et al., 2006; Lin
et al., 2006). Previous work revealed that aberrant nuclear accu-
mulation of cyclin D1 during S-phase promotes transformation
in vitro (Alt et al., 2000) and drives both B cell lymphomas and
mammary carcinomas in mice (Gladden et al., 2006; Lin et al.,
2008). Molecular analysis of these tumors revealed a potential
mechanism wherein the cyclin D1-dependent kinase interferes
with CUL4-dependent CDT1 proteolysis during S-phase (Higa
et al., 2006; Sansam et al., 2006), because of transcriptional
repression of CUL4A and CUL4B; the resulting overexpression
of CDT1 during S-phase triggers DNA rereplication, enhancing
genomic instability and the acquisition of fortuitous mutations
(Aggarwal et al., 2007). A significant feature of the regulatory
pathway leading to loss of CUL4 expression is the noted
dependence on cyclin D1/CDK4 activity. The current work
revealing that phosphorylation ofMEP50 on threonine 5 by cyclin
D1T286A/CDK4 mediates PRMT5-dependent transcriptional
Figure 7. Knockdown of Fbx4 Stabilizes
Nuclear Cyclin D1, Resulting in Increased
PRMT5-Dependent Histone Methylation
(A) Direct western blot analysis of the protein
lysates prepared from control NIH 3T3 or NIH
3T3 harboring Fbx4 knockdown.
(B) Representative immunohistochemistry images
showing dimethyl H4R3 staining of human esoph-
ageal tumor sections. The scale bar represents
100 mm.
(C) Direct western blot analysis of the protein
lysates prepared from TE15 and TE10 cell lines.
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activities of the cyclin D1/CDK4 enzyme.
Although PRMT5/MEP50 was identified through affinity purifi-
cation of D1T286A complexes, it is the demonstration that
MEP50 is a direct substrate for D-type cyclin dependent kinase
that contributes a key advance in our understanding of cyclin
D1-driven tumorigenesis. Phosphorylation of MEP50 on Thr-5
by D1T286A/CDK4 is necessary and sufficient to increase
the intrinsic methyltransferase activity of PRMT5, resulting in
increased H4R3/H3R8 methylation and repression of CUL4A/B
expression. Notably, althoughwe did not detect phosphorylation
of Ser-264 in vivo, mutation of Ser-264 to alanine in MEP50
reduced cyclin D1-dependent induction of PRMT5 activity, sug-
gesting that phosphorylation of this site may also contribute. The
fact that inhibition of PRMT5/MEP50 activity by siRNA or overex-
pression of nonphosphorylatable MEP50 attenuates CUL4
repression is consistent with a model in which PRMT5/MEP50
represents a key molecular target of nuclear cyclin D1/CDK4
during S-phase.
Regulation of PRMT5 by the Cyclin D1-Dependent
Kinase
PRMT5 methylates arginines in multiple proteins, including
myelin basic protein (Ghosh et al., 1988), SM proteins (Friesen
et al., 2001), and p53 (Jansson et al., 2008). However, it is
PRMT5-dependent histone dimethylation that is associated
with transcriptional repression. Of the 11 PRMTs, PRMT5 is
closely associated with transcriptional repression (Pal and Sif,
2007; Pal et al., 2004); its repressive function is attributed to
symmetric dimethylation of histone 4 (arginine 3) and histone 3
(arginine 8) (Krause et al., 2007). These histone modifications
were recently linked with the subsequent recruitment of
DNMT3, linking histone methylation with DNA methylation
(Zhao et al., 2009).
Regulation of PRMT5 function remains poorly understood and
modification of PRMT5 by phosphorylation, acetylation, or ubiq-
uitylation has not been reported. In contrast, association of
PRMT5 with MEP50 is an activating event (Krause et al., 2007).Cancer Cell 18, 329–340In addition, association of COPR5 with
PRMT5 changes the balance of activity
from H3R8 toward H4R3 (Lacroix et al.,
2008). Although PRMT5 is not detectably
modified in a CDK4-dependent manner,
a multiplicity of approaches revealed
MEP50 to be a direct substrate. Thedata provided demonstrate that phosphorylation of Thr-5, and
perhaps Ser-264, of MEP50 contributes to increased PRMT5/
MEP50 methyltransferase activity in cells harboring nuclear
cyclin D1/CDK4. Because addition of purified MEP50 to re-
combinant PRMT5 is sufficient to activate PRMT5 methyltrans-
ferase function (Krause et al., 2007), the most direct model is
that cyclin D1-dependent phosphorylation functions as a switch
to facilitate MEP50-dependent, structural alterations in PRMT5
that contribute to enhanced catalysis or perhaps increased
affinity for substrates, which translates into more efficient
methylation.
Transcriptional Regulation of CUL4A/B by Cyclin D1
Previous work demonstrated that nuclear, active cyclin
D1/CDK4 during S-phase leads to reducedCUL4A/B expression
(Aggarwal et al., 2007). Although the underlying mechanism
remained elusive, a large body of work associating cyclin D1
with transcriptional regulation suggested that regulation could
be direct. For example, cyclin D1 was first noted to associate
with the estrogen receptor (ER) to coordinate ligand-indepen-
dent expression of ER targets independent of CDK activation
(Lamb et al., 2000; McMahon et al., 1999; Zwijsen et al., 1998;
Zwijsen et al., 1997). Subsequently, cyclin D1 was shown to
bind and regulate the activities of androgen receptor (Knudsen
et al., 1999), DMP1 (Hirai and Sherr, 1996), and C/EBPb (Lamb
et al., 2003). Our current work demonstrates that regulation
reflects CDK4-dependent phosphorylation of MEP50, which, in
turn, increases PRMT5-dependent histone methylation of target
genes, reducing their expression. Although previous work sup-
ports a model in which cyclin D1 functions as a molecular bridge
between DNA-bound transcription factors and coactivators or
repressors, our data reveal not only that cyclin D1 occupies
promoter regions of a target gene, but also that regulation
reflects CDK-dependent phosphorylation of a recruited epige-
netic regulatory enzyme. Consistently, recent work utilizing
genome-wide ChIP analysis demonstrated that cyclin D1 is
enriched in regions near the transcriptional start site of a large
number of genes (Bienvenu et al., 2010), providing additional, October 19, 2010 ª2010 Elsevier Inc. 337
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Regulation of PRMT5 by Cyclin D1/CDK4evidence for cyclin D1 directly regulating gene expression. It is
intriguing to note that the strongest H4R3 methylation occurs
near the predicted transcription start site of both CUL4A and
CUL4B.
The role of CDK4, although perhaps unexpected in the context
of transcription, is not totally unexpected in the context of tumor-
igenesis given that CDK activation is central to the function of
cyclin D1 during neoplastic transformation. That MEP50 is
a substrate for cyclin D1/CDK4 makes the PRMT5/MEP50 com-
plex one of a limited number of cyclin D1-dependent substrates.
Previously, only the RB family members (Kato et al., 1993) and
Smad3, a key mediator for TGF-b antiproliferative responses
(Liu and Matsuura, 2005; Matsuura et al., 2004), have been
established as substrates in vitro and in vivo.
Although increased cyclin D1T286A/CDK4-dependent
PRMT5/MEP50 function is required for CUL4 loss and CDT1
overexpression, we cannot rule out the contribution of additional
mechanisms that contribute to CUL4 regulation. For example,
neither cyclin D1 nor PRMT5/MEP50 has intrinsic DNA-binding
properties. Thus, it remains unclear how cyclin D1T286A/CDK4
promotes the targeting to this locus. In addition, we questioned
the possibility that cyclin D1T286Amight result in the recruitment
of histone deacetylases and thereby impact CUL4 expression.
Our results indicated that HDAC inhibition resulted in increased
CUL4 expression regardless of cyclin D1T286A/CDK4, suggest-
ing a nonspecific effect (Figures S2G and S2H).
Signaling Through PRMT5/MEP50 Is Not Limited
to Lymphoid Tumors HarboringMutant Cyclin D1 Alleles
Cyclin D1T286A/CDK4 increases PRMT5 methyltransferase
activity in vivo through MEP50, revealing a pathway whereby
PRMT5 facilitates cyclin D1T286A/CDK4-dependent rereplica-
tion and survival of murine tumors harboring a lymphoid-specific
D1T286A transgene. However, it is important to note that this
mechanism is not restricted to this model system or this partic-
ular cyclin D1 allele for the following reasons. First, knockdown
of Fbx4, the specificity component of the cyclin D1 E3 ligase,
stabilizes nuclear cyclin D1/CDK4 complexes in the nucleus
during S-phase and thereby increases PRMT5-dependent
histone methylation, resulting in CUL4 loss. Second, human
tumors harboring inactivating mutations in Fbx4 and subsequent
nuclear accumulation of endogenous cyclin D1-dependent
kinase, exhibit a dramatic increase in H4R3 methylation. Finally,
cyclin D1/CDK4-MEP50/PRMT5 complexes are observed in
esophageal carcinoma cell lines harboring cyclin D1P287A.
These independent findings implicate aberrant nuclear cyclin
D1 in transcriptional repression of CUL4.
Collectively, our current work supports a model wherein accu-
mulation of nuclear cyclin D1/CDK4 during S-phase triggers
increased PRMT5/MEP50 activity, thereby specifically reducing
CUL4 expression (and triggering downstream stabilization of
CUL4 ligase targets such as CDT1). Our functional analysis
revealed that PRMT5 is necessary for cyclin D1-mediated cell
transformation and further that tumors harboring dysregulated
cyclin D1 exhibit increased PRMT5-dependent histone methyla-
tion. Future efforts to determine the global gene expression
pattern altered through cyclin D1-dependent regulation of
PRMT5 and which of these specifically contribute to neoplastic
growth will be of significant importance.338 Cancer Cell 18, 329–340, October 19, 2010 ª2010 Elsevier Inc.EXPERIMENTAL PROCEDURES
Cell Culture, Transfections, and Plasmids
Cell culture conditions and transfections were performed as previously noted
(Aggarwal et al., 2007). The human PRMT5 Myc-tagged vector was generated
by PCR using primers designed for directional cloning into pCS2-MT plasmid
(in frame with six Myc epitope tags at the N terminus of PRMT5), using PRMT5
cDNA (Open Biosystems) as the template. Human GST-tagged MEP50 vector
was generated by PCR of human MEP50 with primers designed for directional
cloning into pGEX-4T-1 plasmid (in frame with GST tag at the N terminus of
MEP50), using pOTB7-MEP50 (Open Biosystems) as the template. Human
MEP50 Myc-tagged vector was generated by PCR of human MEP50 with
primers designed for directional cloning into pcDNA3 plasmid (in frame with
1X Myc tag at the N terminus of MEP50). Site-directed mutagenesis was
performed with QuikChange Site-Directed Mutagenesis Kit (Stratagene)
according to the manufacturer’s instructions. All clones were sequenced in
their entirety.
Chromatin Immunoprecipitation Assay
For ChIP, cells were cross-linked in 0.75% formaldehyde for 10 min and
quenched with 0.18 mM glycine for 5 min. Cells were harvested in cell lysis
buffer (50 mM HEPES [pH 7.5], 140 mM NaCl, 1 mM EDTA [pH 8.0], 1.0%
Triton X-100, 0.1% SDS, 0.1% deoxycholate, and fresh protease inhibitors)
and chromatin sheared to an average size of 350–600 bp by sonication (3 3
10min cycles of 303 30 s each) at constant output on high setting (Bioruptor).
Sonicated DNA was diluted 3-fold in dilution buffer (20 mM Tris-HCl [pH 8.0],
2mM EDTA [pH 8.0], 1% Triton X-100, 150 mM NaCl, and protease inhibitors)
and was precleared with protein A plus agarose (Millipore). Lysates were
rotated at 4C overnight with 5 mg of polyclonal antibodies specific for H4R3
(Abcam) or H3R8 anti-sera, as described below, including PRMT5 (Abcam),
M2 monoclonal, (Sigma), Brg1 (Santa Cruz), or normal rabbit IgG (Cell
Signaling). After washing, complexes were eluted in 130 ml of elution buffer
(1% SDS plus 100 mM NaHCO3), followed by addition of 100 mg of proteinase
K at 65C overnight for crosslink reversal. The DNA was purified by phenol-
chloroform extraction, and precipitated DNA was analyzed by qPCR. The
primers used for CUL4A and CUL4B have been described in Figure S3D.
Immunoprecipitation and Immunoblot Analysis
Cells were harvested in Tween-20 buffer (50 mM HEPES [pH 8.0], 150 mM
NaCl, 2.5 mM EGTA, 1 mM EDTA, and 0.1% Tween 20), protease, and phos-
phatase inhibitors (1 mM PMSF, 20 U/ml aprotinin, 5 mg/ml leupeptin, 1 mM
DTT, 0.4 mM NaF, and 10 mM b-glycerophosphate), and protein concentration
of samples was determined by BCA assay. Cyclin D1, PRMT5, and MEP50
were precipitated using M2 anti-flag agarose (to recognize flag-tagged
proteins; Sigma-Aldrich), PRMT5 rabbit polyclonal antibody (Abcam), or
c-myc (9E10) andMEP50 rabbit polyclonal antibody (Bethyl Lab), respectively.
Proteins were resolved by SDS-PAGE, transferred to nitrocellulose mem-
branes, and analyzed by immunoblotting. Antibodies used in these studies
were as follows: Fbx4 rabbit polyclonal antibody (Rockland Immunochemi-
cals); cyclin D1 mouse monoclonal antibody D1-72-13G and cyclin D1 mouse
anti-human (Calbiochem); b-actin mouse monoclonal (Sigma-Aldrich); Cul4A
rabbit polyclonal (Bethyl Lab. Inc); Cul4B rabbit polyclonal (ProteinTech Group
Inc); pSP/TP mouse monoclonal (16B4, Biomol); CDK4 (C-22 or H-22), Cdt1,
Brg1, RB, PRMT5 mouse monoclonal, PRMT2, and mSin3a (Santa Cruz);
and H4R3 rabbit polyclonal-ChIP grade, H3K4 rabbit polyclonal, Histone H3
rabbit polyclonal, PRMT1 and PRMT7, and Histone H4 rabbit polyclonal
(Abcam). Anti-H3R8 (corresponding to symmetric dimethylated R8 of human
histone H3) antibody was generated by immunizing rabbits with peptide con-
taining modified histone H3 (YenZym Antibodies, LLC) and subsequent affinity
purification. Antibody binding was visualized by chemiluminescence (Perkin
Elmer). Figures S3A–S3C reveal the specificity of this antibody.
Immunohistochemistry
Human esophageal tumors harboring Fbx4 mutations and normal esophageal
tissue were obtained with informed consent and with Institutional Review
Board approval from the University of Pennsylvania (IRB #803902), Fox Chase
Cancer Center (IRB #98-53), and University of Fukui, Japan (IRB #H190228-
155). Tissue was fixed in 10% buffered formalin and subsequently was
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Regulation of PRMT5 by Cyclin D1/CDK4dehydrated, paraffin embedded, and sectioned. Tissue sections were immu-
nostained as described previously (Aggarwal et al., 2007), with rabbit poly-
clonal H4R3 (Abcam) at 1:500 dilution as the primary antibody.In Vitro Kinase Assay and In Vitro Methyltransferase Assay
Purified GST-MEP50 wild-type, GST-T5A, S176A, S264A, S306A mutants,
andGST-RBwere used as substrates for in vitro kinase reactions (Matsushime
et al., 1994). Cyclin D1/CDK4 kinase complexes were purified from Sf9 cells.
For assessment of PRMT5 methyltransferase activity, PRMT5 complexes
were collected from the indicated sources by immune precipitation. Beads
were washed in Tween-20 buffer followed by methyltransferase buffer
(15 mM HEPES [pH 7.9], 100 mM KCl, 5 mM MgCl2, 20% Glycerol, 1 mM
EDTA, 0.25 mM DTT, and 0.5 mM PMSF). The methylation reaction included
PRMT5 immune complexes on beads, 1 mg recombinant Histone H4 (NEB),
and 2.75 mCi S-adenosyl-L-(methyl-3H)methionine (Amersham Pharmacia) in
a total volume of 25 ml for 1.5 hr at 30C. The reaction mixture was resolved
on a SDS-polyacrylamide gel, and modified histone H4 was detected by fluo-
rography. For the coupled kinase assay/methyltransferase assay, cyclin
complexes were purified from Sf9 cells and mixed with purified recombinant
PRMT5/MEP50 complex (produced in Sf9 cells, BPS Bioscience) or PRMT5
immune precipitated from HeLa cells immobilized on beads. In vitro kinase
assays were performed for 30 min at 30C in kinase buffer. PRMT5-containing
beads were washed into methyltransferase buffer, followed by in vitro methyl-
ation reaction for 2 hr at 30C with 2 mg H4 substrate and 2.75 mCi 3H-SAM.
Methylated H4 was visualized by fluorography or scintillation counting for 3H
incorporation.Foci Formation
Low passage NIH 3T3 cells were transfected with control or murine PRMT5
siRNA (Dharmacon) with HiPerfect (QIAGEN). Twenty-four hours after siRNA
delivery, cells were transfected with 2 mg of the indicated plasmids (pBabe
Ras V12 or pBabe cyclin D1T286A) or empty vector (pBabe puro) using Lipo-
fectamine/Plus Reagent (Invitrogen). Transfected cells were counted after
48 hr, and 2 3 105 cells were plated in duplicate on 35 mm plates in DMEM
containing 5% FBS. Cells were re-fed with DMEM plus 5% FBS every
2 days for 14 days, followed by staining with Giemsa to visualize foci formation.
Foci were counted for duplicate plates; in the figures, error bars represent ±
standard deviation and asterisks indicate p < 0.05, as determined by Student’s
t test. For MEP50 overexpression assays, NIH 3T3 cells were transfected with
2 mg of wild-type MEP50 or phosphorylation-deficient MEP50 mutant T5A or
S264A, along with empty vector or Ras V12 and cyclin D1T286A constructs,
as indicated. Cells were seeded and foci formation was analyzed as described
above.Real-Time Quantitative PCR Analysis of Gene Expression
RNA isolation was performed using standard protocols. DNA fragments were
generated by reverse transcriptase PCR (RT-PCR; SuperscriptTM, Invitrogen).
Mixed primer/probe sets for human CUL4A/B and 18S rRNA were used
to measure the levels of these transcripts using the Applied Biosystems
7900HT sequence detection system, in accordance with the manufacturer’s
instructions. Primers used for detection of human CUL4A and CUL4B were
described previously (Aggarwal et al., 2007).siRNA and Methyltransferase Inhibitor Experiments
siGENOME SMARTpool targeting PRMT5 and MEP50 or control siRNA were
purchased from Dharmacon. HeLa cells were treated with indicated siRNA
or methyltransferase inhibitors, MTA (Sigma) or AMI-1 (Calbiochem), for
24 hr followed by transfection and synchronization of cells in G1 and S-phases.
For targeting 30 UTR region of human MEP50, siRNA (50-CUCCUUACCA
UUAAACUGA-30) was designed and purchased from Sigma.SUPPLEMENTAL INFORMATION
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